Crispri-based gene silencing therapy for myotonic dystrophy
A novel CRISPRi-based therapy utilizing compact Cas9 variants for precise gene silencing of DMPK in myotonic dystrophy, delivered via myo-tropic AAV vectors. This approach aims to reduce disease symptoms and improve patient outcomes.
Overview
This innovative solution leverages CRISPR interference (CRISPRi) technology to target and silence the DMPK gene, which is implicated in myotonic dystrophy type 1 (DM1). Utilizing compact Cas9 variants from S. aureus and S. uberis, this therapy overcomes conventional size limitations of gene silencing cassettes, enabling delivery via adeno-associated virus (AAV) vectors. This targeted approach promises to significantly reduce DMPK expression, potentially alleviating disease symptoms and improving quality of life for patients.
Technical specifications
Key features:
- Utilizes compact dCas9-KRAB variants from S. aureus and S. uberis for efficient gene silencing
- Delivered via novel myo-tropic AAV vectors tailored for effective targeting of muscle tissues
- Incorporates optimized gRNAs identified through a tiling screen for maximum repression of the DMPK promoter
- Verification of specificity and efficacy through HCR-FlowFISH and RNA sequencing in patient-derived myoblasts
Technology readiness level
The technology is currently at TRL 3, having demonstrated proof-of-concept efficacy in preclinical studies, including in vitro validation and initial testing in mouse models. Further development will focus on refining the system for in vivo therapeutic applications and advancing towards clinical trials.
About Duke University
Duke University is a mid-sized, comprehensive private research university in Durham, North Carolina, anchored by a globally recognized academic medical center. Co-located campus and clinical facilities enable rapid bench-to-bedside translation, and shared core laboratories are accessible to external partners. Proximity to Research Triangle Park links Duke to a dense network of R&D-intensive companies, supported by centralized corporate engagement for sponsored research and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD. A dedicated technology transfer office supports IP strategy, licensing, startups, and industry collaboration.
Inquire about this partnering listing
Industry applications
delivered to your inbox.